logo
Plus   Neg
Share
Email

Genentech: Tecentriq, Avastin Combination Study Meets Co-primary Endpoints

Genentech, a member of the Roche Group (RHHBY), said Tecentriq in combination with Avastin, as a treatment for people with unresectable hepatocellular carcinoma who have not received prior systemic therapy, showed statistically significant and clinically meaningful improvements in overall survival and progression-free survival compared with standard-of-care sorafenib in a Phase III IMbrave150 study. Safety data for the combination was consistent with the safety profiles of the individual medicines.

In July 2018, the U.S. FDA granted Breakthrough Therapy Designation for Tecentriq in combination with Avastin in hepatocellular carcinoma.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration approved the first contact lens developed for slowing the progression of myopia or nearsightedness in children between the ages 8 and 12 years at the initiation of treatment. This could also help in ultimately reducing risk of developing other eye problems. The regulator granted approval for CooperVision Inc.'s MiSight contact lens. Amazon plans to more than double its corporate workforce in Las Vegas by creating 125 additional jobs in the city. The e-commerce giant recently opened a new 30,000 square foot office in Town Square in downtown Las Vegas and plans to expand its corporate workforce in the area to support its Human Resources division. Amazon also said it will donate $100,000 to two food bank partners. Consumer Reports has once again recommended Tesla's Model 3 and Model S sedans as reliable, after the vehicles were previous downgraded by the organization. Consumer Reports said that the two sedans regained its recommendation due to improved reliability reports from owners of the cars, based on the results of its annual Auto Reliability Survey that were announced Thursday.
Follow RTT
>